Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer

Cancer Treatment Communications

Volumn 6, Issue , 2016, Pages 20-23

  Bagley, Stephen J ^a   Kosteva, John A ^a   Evans, Tracey L ^a   Langer, Corey J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Immune thrombocytopenia; Immune related adverse events; Nivolumab; Non small cell lung cancer; Programmed death 1

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; IMMUNOGLOBULIN; NIVOLUMAB; PACLITAXEL; ROMIPLOSTIM;

ADRENAL METASTASIS; ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD CELL COUNT; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE EXACERBATION; HEMOPTYSIS; HUMAN; MALE; MEDIASTINUM LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SOFT TISSUE TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TUMOR VOLUME;

EID: 84958985225     PISSN: 22130896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrc.2016.02.009     Document Type: Article

References (12)

1. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373:1627-1639.
2. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373:123-135.
3. Gordon I.O., Wade T., Chin K., et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol. Immunother. 2009, 58:1351.
4. Akhtari M., Waller E.K., Jaye D.L., et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J. Immunother. 2009, 32:322.
5. Delyon J., Mateus C., Lambert T. Hemophilia A induced by ipilimumab. N. Engl. J. Med. 2011, 365:1747-1748.
6. Kanameishi S., Otsuka A., Nonomura Y., et al. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann. Oncol. 2015, 10.1093/annonc/mdv580.
7. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008, 371:395-403.
8. Naidoo J., Page D.B., Li B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 2015, 26:2375-2391.
9. Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:2018-2028.
10. Wang H.B., Shi F.D., Li H., et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gracis. J. Immunol. 2001, 166:6430-6436.
11. Luhder F., Hoglund P., Allison J.P., et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp. Med. 1998, 187:427-432.
12. Weber J.S., Antonia S.J., Topalian S.L., et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J. Clin. Oncol. 2015, 33. (suppl; abstr 9018).